Use of the FoundationOne next-generation sequencing (NGS) assay to detect actionable alterations leading to clinical benefit of targeted therapies for relapsed and refractory breast cancer

被引：0

作者：

Ross, Jeffrey S.

Cristofanilli, Massimo

Downing, Sean

Yelensky, Roman

Lipson, Doron

Otto, Geoff

Palmer, Gary A.

Ali, Siraj M.

Miller, Vincent A.

Stephens, Phil

机构：

[1] Albany Med Coll, Albany, NY 12208 USA

[2] Thomas Jefferson Univ, Jefferson Med Coll, Philadelphia, PA 19107 USA

[3] Fdn Med, Cambridge, MA USA

[4] Fdn Med Inc, Cambridge, MA USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1009

引用

页数：1